Both VIXY and VXX provide exposure to short-term VIX futures, targeting increases in expected S&P 500 volatility rather than equity ownership. VIXY is structured as an ETF (commodity pool), while VXX is an ETN (exchange-traded note), introducing counterparty credit risk for the latter.

FTH shares collapsed -18.33% during regular trading to $25.70, extending yesterday's -4.98% drop and marking a brutal two-day selloff from the $35+ range. The crash follows a parabolic speculative run-up that propelled shares from ~$13 in mid-June to a 52-week high of $37.90 on July 13, fueled by the company's rebranding to Faeth Therapeutics.

ELVA is down approximately -19.22% during Thursday's regular trading session, pulling back to roughly $9.50 after closing at $11.76 on Wednesday. The sell-off follows Wednesday's massive +49% surge, which was fueled by a newly announced commercial agreement with Amazon to deploy Electrovaya's Infinity Battery Technology and a warrant deal worth up to $280 million in future orders.

ABSI shares are down -16.19% in regular trading on Thursday, extending a steep multi-day selloff that has now erased roughly 29% of the stock's value in just over a week. The decline is primarily driven by aggressive profit-taking after a massive +233% year-to-date rally through early July, with the stock retreating from its $12.06 52-week high as momentum traders and short-term investors lock in gains.

MXL plunged -14.53% intraday on Thursday, falling from Wednesday's close of $88.84 to $75.93 during regular trading hours, accelerating a multi-day selloff. The drop follows Wednesday's -4.05% decline and premarket weakness, reflecting heavy profit-taking after the stock's extraordinary +406% year-to-date rally left valuations stretched at 11.4x forward sales.

FCEL shares tumbled -14.81% during Thursday's regular session, falling from a prior close of $20.25 to approximately $17.25, accelerating a multi-day selloff that began after the company's $225M dilutive equity offering was priced at $21 per share earlier this month. The decline deepened as FCEL broke decisively below the $21 offering price, a key psychological and technical level, triggering additional selling pressure and stop-loss cascades throughout the session.

AXTI dropped -14.51% during regular trading, falling from a prior close of $53.42 to approximately $45.67 on elevated intraday volume. A broad semiconductor sector sell-off dragged the group down roughly -4.7%, with AXTI leading decliners as the weakest name in the sector.

BB plunged -12.50% during regular trading hours to $9.31, extending a multi-session selloff from the July 15 close of $10.64. The primary catalyst is aggressive profit-taking following a ~180%+ year-to-date surge, as traders unwind momentum positions after the stock peaked near $13.59.

ATAI surged approximately +31.72% to $7.06 after Eli Lilly confirmed it will acquire the psychedelic drug developer in a deal valued at up to $3.8 billion. The rally was ignited in premarket trading following a Wednesday evening Bloomberg report that Lilly was in advanced buyout talks, with the official announcement confirming terms Thursday morning.

ABT surged +12.46% during Thursday's regular session after reporting Q2 2026 earnings premarket that beat estimates across key metrics. Adjusted EPS of $1.31 topped the $1.28 consensus, while revenue of $12.59B exceeded the $12.52B forecast, reflecting +13% reported sales growth year-over-year.

CHRN is trading down approximately -13.03% during regular market hours, falling from yesterday's close of $29.63 to around $25.77, giving back nearly half of the prior session's explosive gains. The sell-off follows yesterday's +28.77% surge, which was fueled by ASML's strong earnings and raised 2026 outlook that reignited enthusiasm across AI infrastructure names.

WDC is down -4.71% in regular trading today, compounding yesterday's -8.78% plunge as a memory-sector rout deepens. The selloff is driven by aggressive profit-taking after memory stocks surged Tuesday on IBM's warning that customers were redirecting spending toward servers, storage, and memory chips.

ASTS shares tumbled -9.76% on Thursday, extending an after-hours plunge of approximately -13% that began Wednesday evening after the company announced a $1 billion convertible senior notes offering due 2034. The primary catalyst is the convertible note raise, which spooked investors over potential future share dilution — this marks ASTS's second $1 billion convertible offering in recent months, reigniting concerns about its heavy cash burn and capital needs.

IPAY gained approximately 12% over the trailing 30-day period, rebounding sharply from a June low near $42 to trade above $49. The quarterly trend shows a more moderate gain of roughly 4–5%, reflecting a volatile path marked by a sharp sell-off in early June followed by a powerful recovery.

VXX is an exchange-traded note (ETN) issued by Barclays that tracks the S&P 500 VIX Short-Term Futures Index, providing exposure to a daily rolling blend of first- and second-month VIX futures contracts. The product is structurally designed as a short-term tactical instrument for hedging or speculation, and is not suitable for buy-and-hold strategies due to persistent contango decay that erodes value over time.

Target price: $30 per share, representing a roughly 40-45% gain from recent levels near $21, a round psychological level the ETF has crossed multiple times over the past year. Strongest bullish factor: A sudden spike in equity market volatility — driven by geopolitical shock, recession fears, or a rapid equity sell-off — would directly lift VIX futures prices and propel VIXY higher.

VIXY tracks the S&P 500 VIX Short-Term Futures Index, providing exposure to front-month and next-month VIX futures contracts rather than the spot VIX itself. The ETF holds approximately five assets, primarily Cboe VIX futures contracts alongside cash equivalents and Treasury bills, and carries an expense ratio of 0.85%.

TowneBank shares are trading near $36.10, up approximately 2.8% over the past 30 days, reflecting steady investor confidence in the Virginia-based regional bank. The company completed three strategic bank acquisitions in the past year, adding roughly $3.8 billion in assets and expanding its footprint across the Carolinas.

Maximus shares have declined approximately 5.3% over the last 30 days, closing at $57.97 on July 15, 2026, extending a year-to-date decline of roughly 33%. The company continues to raise earnings guidance for fiscal 2026, now forecasting adjusted EPS between $8.25 and $8.55, supported by AI-driven automation and margin expansion.

Price target in focus: $500 per share — a psychologically significant round number roughly 33% above Ferrari's recent closing price near $375 and just below the stock's 52-week high of $519.10. Strongest bullish factors: Record order backlogs extending into 2027, industry-leading EBITDA margins approaching 39%, disciplined scarcity-driven production, and successful hybrid model adoption now representing over 60% of deliveries.